|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of multiple hormones such as gastrin, insulin, pancreatic polypeptide and somatostatin was also observed throughout the neoplastic cell population, while the endocrine component of the neoplasm was predominantly positive for glucagon.
|
30898297 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immnohistochemical staining of tumor tissue was positive for glucagon.
|
31517863 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The workup of the patient revealed a tumor localized in the head of the pancreas, and glucagon serum levels were elevated.
|
30124507 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Glucagon-like-peptide-1 (GLP) receptor analogs are the latest agents being used in the detection of insulinomas, with initial reports suggesting high sensitivity due to universal GLP1 receptor expression on these tumors.
|
29877881 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-2(1-33) treatment in animals with a pre-induced cancer showed that GLP-2(1-33) may promote growth of existing neoplasia.
|
29231791 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor expression of glucagon and somatostatin receptor subtype 2 and 3 messenger RNA was markedly upregulated.
|
29688432 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 analogue exendin-4, a glucagon-like peptide 1 receptor (GLP-1R) agonist which shares 53% sequence with GLP-1, plays an essential role in human tumors.
|
30119208 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Hypercalcemia in Glucagon Cell Hyperplasia and Neoplasia (Mahvash Syndrome): A New Association.
|
30032256 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In patients with glucagon-producing tumors (glucagonomas), the most conspicuous signs are skin lesions (necrolytic migratory erythema), while in subjects with inactivating mutations of the glucagon receptor, pancreatic swelling may be the first sign; neither condition is necessarily associated with disturbed glucose metabolism.
|
28108603 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, hyperglucagonemia is also observed in other clinical conditions than diabetes, including nonalcoholic fatty liver disease, glucagon-producing tumors and after gastric bypass surgery.
|
27611762 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
At ≤20°C, glp-1(ar202) is wild-type, whereas at 25°C it forms a germline stem cell⁄progenitor cell tumor reminiscent of human cancer.
|
26120834 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
GLP-1 levels significantly increased after surgery (149.96 ± 31.25 vs 220.23 ± 27.55) (P < 0.05), while GIP levels decreased but not significantly. p53 gene expression significantly increased in the duodenal mucosa (P < 0.05, 2.06 fold) whereas the tumor growth factor-β gene expression significantly increased (P < 0.05, 2.52 fold) in the ileal mucosa after surgery.
|
26078577 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Considering tumor heterogeneity, the percentage of ALK amplified tumor cells ranged from 11% to 43%, with a mean gene copy gain (GCG ± SD) of 6.9 ± 0.8 and no signal differences between the epithelial (6.5 ± 0.9) and the sarcoma-like components (6.8 ± 0.9) of tumors.
|
22705117 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed a previously undescribed multicentric glucagon-producing tumor disease that is not related to MEN1.
|
18957496 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The majority of these tumor cells were immunohistochemically positive for insulin and negative for glucagon.
|
19350420 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
And the AAA and the GCG haplotypes also respectively have significant influences on tumor size and ER status.
|
19903360 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The importance of the GLP-2R for tumor growth was also examined in Apc(Min/+) mice chronically treated with exogenous GLP-2 and in Apc(Min/+):Glp2r(-/-) mice.
|
18829546 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The rate constant for baseline catecholamine secretion was 20-fold higher in VHL than in MEN 2 tumors (0.359 +/- 0.094 vs. 0.018 +/- 0.009 day(-1)), but catecholamine release was responsive only to glucagon in MEN 2 tumors.
|
18854424 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The other patients were nonsymptomatic and showed multiple glucagon-expressing neoplasms.
|
16699310 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Silent polymorphisms at codon 11 (CCC --> CCT; Pro --> Pro) and codon 75 (GCG --> GCA; Ala --> Ala) were frequently detected in tumors as well as in normal tissues.
|
12699056 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All tumors were positive for panendocrine immunohistochemistry markers (chromogranin A and/or synaptophysin); 35% of NETs demonstrated focal positivity for pancreatic polypeptide, somatostatin, insulin, and/or glucagon; and no immunostaining for pancreatic and gastrointestinal hormones was observed in 65% of tumors.
|
9665483 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor cells were positive for immunoreactive insulin and glucagon.
|
9438006 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transgenic mice expressing large T antigen in secretin cells developed poorly differentiated neuroendocrine tumors of the small intestine, well differentiated colonic tumors containing glucagon-expressing cells, and insulin-producing tumors in pancreas.
|
7822327 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No mutations were observed in the cytoplasmic domains of the TSH-R, except for a neutral base substitution in codon 460 (GCG [Ala]-->GCA [Ala]) in 3 tumors, which was also present in constitutional DNA from the affected individuals.
|
8501149 |
1993 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The nature of selective hyper-expression of HMG-17 in glucagon but not in insulin-producing tumor tissue remains to be clarified.
|
2169420 |
1990 |